Marinus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Marinus Pharmaceuticals

11/08/2022 14:33

* Marinus Pharmaceuticals Inc  MRNS.OQ  reported a quarterly
adjusted loss of $1.06​​ per share for the quarter ended in
June. The mean expectation of ten analysts for the quarter was
for a loss of 69 cents per share.
    * Revenue fell 6% to $1.79 million from a year ago; analysts
expected $2.32 million. 
    * Marinus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.06​.
    * The mean earnings estimate of analysts had fallen by
about 49.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Marinus Pharmaceuticals Inc shares had risen by 22.5% this
quarter and lost 50.1% so far this year.
    * The company reported a quarterly loss of $39.43 million.
    * Wall Street's median 12-month price target for Marinus
Pharmaceuticals Inc is $28.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 10 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 11
at 01:33 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.69          -1.06          Missed
 Mar. 31 2022      -0.85          -0.52          Beat
 Dec. 31 2021      -0.76          -0.77          Missed
 Sep. 30 2021      -0.73          -0.53          Beat